P11 promoter methylation predicts the antidepressant effect of electroconvulsive therapy.

ABSTRACT: Although electroconvulsive therapy (ECT) is among the most effective treatment options for pharmacoresistant major depressive disorder (MDD), some patients still remain refractory to standard ECT practise. Thus, there is a need for markers reliably predicting ECT non/response. In our study, we have taken a novel translational approach for discovering potential biomarkers for the prediction of ECT response. Our hypothesis was that the promoter methylation of p11, a multifunctional protein involved in both depressive-like states and antidepressant treatment responses, is differently regulated in ECT responders vs. nonresponders and thus be a putative biomarker of ECT response. The chronic mild stress model of MDD was adapted with the aim to obtain rats that are resistant to conventional anti

SUBMITTER: Neyazi A 

PROVIDER: S-EPMC5802592 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature